Professors Tom Powles and Peter Schmid recently delivered results from their phase three clinical trials during Sunday's Presidential Symposium to over 30,000 attendees at the European Society for Medical Oncology (ESMO) ...
Sep 16, 2024
0
38
The epidermal growth factor receptor tyrosine kinase inhibitor aumolertinib demonstrated improved progression-free survival compared to placebo without any significant new adverse reactions, according to data from the POLESTAR ...
Sep 11, 2024
0
22
Phase 2 results from the NeoCOAST-2 study have demonstrated that the combination of durvalumab with Dato-DXd yielded the highest pathological complete response rates among the tested regimens.
Sep 8, 2024
0
34
Many countries with national health care systems or payers such as insurance companies use cost-effectiveness analyses to decide whether to cover new medicines, balancing treatment costs with potential health benefits.
May 30, 2024
0
41
British pharmaceutical giant AstraZeneca on Thursday said net profit jumped 21 percent in the first three months of the year thanks to strong growth in sales of cancer drugs.
Apr 25, 2024
0
47
A new research paper was published in Oncotarget entitled, "Durvalumab and tremelimumab before surgery in patients with hormone receptor positive, HER2-negative stage II–III breast cancer."
Mar 27, 2024
0
40
A first-in-human trial led by The University of Western Australia has found injecting an immunotherapy drug directly into the bladder wall to treat cancer is viable and safe.
Mar 14, 2024
0
67
A new study identified a set of 140 genes that may help predict enhanced disease-free survival in patients with non-small cell lung cancer (NSCLC) treated with a combination of immunotherapy and low-dose radiation. The results, ...
Feb 23, 2024
0
51
A newly identified genetic marker could potentially predict which patients are likely to respond to immunotherapy in cancer types that have lacked such tools until now, according to a new study published in Cancer Immunology ...
Feb 13, 2024
0
50
A specific combination of targeted therapy and immunotherapy may better help patients with non-small cell lung cancer (NSCLC) overcome inherent immune resistance and reinvigorate anti-tumor activity, according to a new study ...
Feb 13, 2024
0
50
